Teplizumab-mzwv: Perspective on clinical practice and use at a single institution

Authors

  • Jamie L. Felton MD Department of Pediatrics, Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indianapolis, Indiana, USA Author
  • Alex Tuttle MD MEd Department of Pediatrics, Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indianapolis, Indiana, USA Author
  • Emily K. Sims MD Department of Pediatrics, Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indianapolis, Indiana, USA Author https://orcid.org/0000-0002-4393-954X

DOI:

https://doi.org/10.69734/59hkbn82

Keywords:

teplizumab, type 1 diabetes, type 1 diabetes prevention, immunotherapy, early-stage type 1 diabetes

Abstract

Type 1 diabetes (T1D) is an autoimmune disease characterized by destruction of insulin-producing beta cells in the pancreas. Early intervention with teplizumab-mzwv (brand name Tzield) can be considered to delay the need for insulin therapy for patients with Stage 2 T1D ≥8 years of age. Eligibility requires the presence of at least two islet autoantibodies in addition to evidence of dysglycemia, but without meeting Stage 3 T1D glycemic criteria.  Clinical practice and experience with this treatment is expanding; however, approval, access, administration, and subsequent monitoring practices remain variable in general practice. Here we present a brief discussion regarding our experience with teplizumab-mzwv at the Riley Hospital for Children at Indiana University Health.

Author Biographies

  • Jamie L. Felton MD, Department of Pediatrics, Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indianapolis, Indiana, USA

    Assistant Professor of Pediatrics

  • Alex Tuttle MD MEd, Department of Pediatrics, Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indianapolis, Indiana, USA

    Assistant Professor of Clinical Pediatrics

  • Emily K. Sims MD, Department of Pediatrics, Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indianapolis, Indiana, USA

    Associate Professor of Pediatrics

References

Smartphone users - link to article is at the end of the reference list

Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015 Oct;38(10):1964-74. DOI: 10.2337/dc15-1419.

Haller MJ, Bell KJ, Besser REJ, et al. ISPAD clinical practice consensus guidelines 2024: screening, staging, and strategies to preserve beta cell function in children and adolescents with type 1 diabetes. Horm Res Paediatr. 2024 Dec 11:1-30. DOI: 10.1159/000543035.

American Diabetes Association Professional Practice C. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabetes Care. 2025 Jan 1;48(Supplement_1):S27-S49. DOI: 10.2337/dc25-S002.

Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves beta-cell function. Diabetes Care. 2023 Oct 1;46(10):1848-56. DOI: 10.2337/dc23-0675.

Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019 Aug 15;381(7):603-13. DOI: 10.1056/NEJMoa1902226.

Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021 Mar 3;13(583). DOI: 10.1126/scitranslmed.abc8980.

Tzield Product Insert. 11/20/24, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf.

Mehta S, Ryabets-Lienhard A, Patel N, et al. Pediatric Endocrine Society statement on considerations for use of teplizumab (Tzield) in clinical practice. Horm Res Paediatr. 2024 Apr 30:1-12. DOI: 10.1159/000538775.

Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care. 2024 Aug 1;47(8):1276-98. DOI: 10.2337/dci24-0042.

Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes. 2022 Apr 1;71(4):610-23. DOI: 10.2337/dbi20-0054.

Image of the first page of the paper by Felton et al

Downloads

Published

2025-05-31

Issue

Vol. 2 No. 2 (2025): SMART-MD Journal of Precision Medicine (Spring 2025): Diabetes Melitus

Section

SMART Medical and Systems Review

License

Copyright (c) 2025 SMART-MD Journal of Precision Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Felton, J. L., Tuttle, A., & Sims, E. K. (2025). Teplizumab-mzwv: Perspective on clinical practice and use at a single institution. SMART-MD Journal of Precision Medicine, 2(2), e149 - e157. https://doi.org/10.69734/59hkbn82